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Statement of translational relevance  
Characteristic features of malignant gliomas are their immunosuppressive phenotype and 
infiltrative growth. Factors like transforming growth factor beta (TGF-)are relevant in both 
processes. Here, we show that this is likewise the case for 4IgB7H3, a novel member of the 
B7-family of costimulatory proteins. We demonstrate B7H3 expression in vivo by 
glioblastoma and endothelial cells and show a correlation with the grade of malignancy and 
an association with worse clinical outcome. As opposed to other tumors and dendritic cells, 
4lgB7H3 is functional in immune and invasion paradigms both cell surface-bound and in a 
soluble form of 93 kDa. The soluble form is demonstrated to lack the intracellular and the 
transmembrane domain and was identified in the supernatant of long-term and primary 
glioma cells. In summary, 4lgB7H3 is an interesting candidate for diagnostic and therapeutic 
purposes and pivotal for the glioma immune escape as well as gliomas cell invasiveness.  
 
Abstract  
Purpose 
Recent work points out a role of B7H3, a member of the B7-family of costimulatory proteins, 
in conveying immunosuppression and enforced invasiveness in a variety of tumor entities. 
Glioblastoma is armed with effective immunosuppressive properties resulting in an impaired 
recognition and ineffective attack of tumor cells by the immune system. In addition, extensive 
and diffuse invasion of tumor cells into the surrounding brain tissue limits the efficacy of local 
therapies. Here, 4IgB7H3 is assessed as diagnostic and therapeutic target for glioblastoma.  
Experimental Design  
In order to characterize B7H3 in glioblastoma we perform analyses not only in glioma cell 
lines and glioma initiating cells, but also in human glioma tissue specimens.  
Results 
B7H3 expression by tumor and endothelial cells correlates with the grade of malignancy in 
gliomas and with poor survival. Both, soluble 4IgB7H3 in the supernatant of glioma cells as 
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well as cell-bound 4IgB7H3 are functional and suppress natural killer cell-mediated tumor cell 
lysis. Gene silencing showed that membrane and soluble 4IgB7H3 convey a proinvasive 
phenotype in glioma cells and glioma initiating cells in vitro. These proinvasive and immuno-
suppressive properties were confirmed in vivo by xenografted 4IgB7H3 gene silenced glioma 
initiating cells, which invaded significantly less into the surrounding brain tissue in an 
orthotopic model and by subcutaneous injected LN-229 cells, which were more susceptible 
to NK-cell mediated cytotoxicity compared with unsilenced control cells.  
Conclusions 
Because of its immunosuppressive and proinvasive function, 4IgB7H3 may serve as a 
therapeutic target in the treatment of glioblastoma.  
 
Introduction  
One of the key biological features of glioblastoma is its ability to suppress the immune 
system resulting in an impaired recognition and attack of the tumor cells by the immune 
system. A number of factors have been identified within the last two decades that are held 
responsible for the immunosuppressive nature of glioblastomas [1-8]. Transforming growth 
factor-TGF- turned out to induce apoptosis in T-cells, to downregulate costimulatory 
proteins on cytotoxic T-cells, natural killer (NK) cells and glioma cells as well as to upregulate 
immunosuppressive ligands on glioblastoma cells. In addition to the immunosuppressive 
properties, invasion of tumor cells into the surrounding brain tissue is another hallmark of 
human glioblastoma. This invasive behaviour limits the feasibility of local treatment like 
surgical tumor resection or involved-field radiotherapy. Glioblastoma cells usually invade as 
single cells migrating along white matter tracts implicating the involvement of integrin-
mediated signalling pathways and the degradation of components of the extracellular matrix 
by matrix metalloproteinases (MMP). Recently, two isoforms of a novel member of the B7-
family of costimulatory proteins, 2IgB7H3 and 4IgB7H3, have been identified [9, 10]. The 
latter was more widely expressed in human maturating dendritic cells (DC), T-cells and many 
human tumor cell lines including glioblastoma [11]. 4IgB7H3 was initially supposed to convey 
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T-cell activation and to induce IFN- production, but more recent evidence suggests that 
4IgB7H3 expressed by different human malignancies suppresses NK cells and cytotoxic T-
cells. In this regard, NK-mediated lysis of neuroblastoma cell lines was enhanced by 
4IgB7H3 neutralizing antibodies [12]. High expression of 4IgB7H3 is associated with a poor 
prognosis in different tumor entities [13-17]. Apart from the expression on tumor cells, 
4IgB7H3 is also specifically upregulated on tumor endothelia [18]. 
The ligand for B7H3 has not been identified yet. It was postulated that the ligand is 
expressed on activated T-cells [9]. Hashiguchi et al. [19] delineated Triggering receptor 
expressed on myeloid cell-like transcript 2 (TLT-2) to be this receptor, but the interaction of 
B7H3 and TLT-2 resulted in T-cell activation, which could not explain its immunosuppressive 
action. Moreover, the physical interaction of B7H3 and TLT-2 was not confirmed [20]. Lastly, 
a soluble form of B7H3 was described to be expressed by human immune cells and by a 
variety of different tumor cells. This soluble form is cleaved by MMP from the cell surface and 
is detected in increased levels in the serum of patients with non-small cell lung carcinoma 
compared with healthy controls and correlated with the tumor burden [21-23].  
Factors like TGF-are relevant in both processes, immunosuppression and invasiveness. 
Here, we demonstrate that this is likewise the case for 4lgB7H3. We show B7H3 expression 
in vivo by glioblastoma and endothelial cells. 4IgB7H3 was until date only detected in the 
glioblastoma cell lines U251, A172 and U87 [10]. Furthermore expression of B7H3 in human 
glioma correlates with the grade of malignancy of astrocytic tumors, ranging from WHO 
grade II to IV. Importantly, 4IgB7H3 is functional by suppressing NK cell-mediated tumor lysis 
in vitro and in vivo. Moreover, glioblastoma-derived soluble 4IgB7H3 suppresses NK cell-
lysis. So far, the soluble form in monocytes, DC and activated T-cells was published to be 
16.5 kDa [24]. This fragment differs from the 93 kDa fragment detected in the supernatant of 
glioma initiating cell cultures and glioma cell lines with commercial antibodies. This 93 kDa 
fragment was not cleaved by MMP from the surface of glioblastoma cells, but by serum 
endopeptidases. Finally, high B7H3 expression correlates with a lower invasion of CD8 
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positive cells in human glioblastoma tissue compared with low B7H3 expressing 
glioblastomas and 4IgB7H3 exerts a proinvasive effect on glioblastoma cells in vitro and 
more important in vivo.  
 
Material and Methods  
Cells and cell culture 
LN-229 glioma cells were kindly provided by Dr. N. de Tribolet (Lausanne, Switzerland). The 
cell line was maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal calf 
serum and penicillin (100 IU/mL)/streptomycin (100 lg/mL) [25]. For the generation of glioma-
initiating cell (GIC) cultures, tumor samples were obtained from adult patients diagnosed with 
glioblastoma after informed consent. The tumor and the GIC culture methods were modified 
from Svendsen et al. [26] as previously described [27]. Glioma characteristic chromosomal 
abnormalities have been verified by array comparative genome hybridization (B. 
Radlwimmer, Department of Molecular genetics, German Cancer Research Center 
Heidelberg). Lentiviral knock-down of 4IgB7H3 and control knock-down cells were produced 
with lentiviral sh 4IgB7H3 and control particles from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA; Cat. no.: sc-45444-V and sc-108080). The unselected 4IgB7H3 knock-down cells 
were named sh 4IgB7H3 pool cells. From these cells a clonal knock-down was selected with 
a higher knock-down rate, which was termed sh 4IgB7H3 clone19. Human Cerebral 
Microvascular Endothelial Cells (HCMEC) and Human Brain Vascular Pericytes were 
purchased from Sciencell (Carlsbad, CA, USA). 
 
Lysates for immunoblots and cell culture supernatants were prepared as described 
previously [28, 29]. Briefly, supernatants were generated for 72 h after plating 3x106 cells in 
serum-free medium. Serum-free supernatants were concentrated with the Centriplus 
centrifugal filter device YM-3 (3000-Da cut-off; Millipore, Schwalbach, Germany). Afterwards, 
a Bradford assay was performed to assure that equal amounts of supernatant-derived 
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protein were used for the NK cell lysis assays or immunoblot analysis. To unravel the 
mechanisms how 4IgB7H3 is cleaved by glioblastoma cells and how 4IgB7H3 is regulated 
1.25x106 LN-229 cells were seeded in serum-free medium and the following compounds and 
treatments were used: 
1. To evaluate hypoxia cells were incubated for 48 h in serum-free medium under 
hypoxic conditions at 1 % O2  and compared with cells that were kept at 21 % O2. 
2. To evaluate the influence of PKC activation, cells were incubated with phorbol 12-
myristate 13-acetate (PMA) (Sigma-Aldrich, Taufkirchen, Germany) diluted in DMSO 
at a final concentration of 100 nM for 48 h [30]. 
3. The influence of TGF- inhibition was tested with LY 2157299, a TGF- receptor 
kinase I inhibitor at 25 nM (Axon Medchem BV, Groningen, The Netherlands) (30) or 
the synthetic furin inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethylketone (dec-
RVKR-cmk) (Bachem, Heidel-berg, Germany), which was diluted in methanol. Cells 
were incubated at 15 µM. New furin inhibitor was added every 12 h [31]. 
4. To examine whether 4IgB7H3 is cleaved by MMP, the MMP inhibitor ilomastat [22]  
was used at concentrations of 5-10 µM (Chemicon International, Temecula, CA). 
Respective DMSO controls were included. 
Afterwards, cells were collected to perform qRT-PCR, immunoblots of supernatants and 
lysates and flow cytometry analysis. All compounds used were shown to be functional in 
other assays. 
 
Immunoblot analysis 
Cells were lysed in 50 mM Tris–HCl (pH 8) containing 120 mM NaCl, 5 mM EDTA, 0.5% 
Nonidet P-40, 2 µg/ml aprotinin, 10 µg/ml leupeptin (Sigma-Aldrich), and 100 µg/ml 
phenylmethylsulfonyl fluoride (PMSF). Protein levels were analyzed by immunoblot using 30 
µg of protein per lane with the respective antibodies in the concentrations recommended by 
the manufacturer [29]. The antibodies used were goat polyclonal anti-human B7H3 (R&D, 
Minneapolis, MN, USA) and rabbit anti-human anti-B7H3 antibody HPA 017139 (Atlas 
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Antibodies, Stockholm, Sweden). Protein bands were visualized using horseradish 
peroxidase-coupled secondary antibodies (Sigma-Aldrich). Equal protein loading was 
ascertained by Ponceau S staining as well as alpha-tubulin stainings with mouse anti--
tubulin antibody (Sigma Aldrich) and rabbit anti -actin antibody (Cell Signalling, Danvers, 
MA, USA). 
 
Exosome isolation  
Serum free conditioned medium from human glioblastoma cells was collected after 48 h. 
Microvesicles were purified by differential centrifugation steps (300g/10min; 2000g/20min 
and 10,000g/30min), pelleted by ultracentrifugation at 175,000g for 60min and washed in 
PBS. Exosomes were identified by immunoblotting using the exosomal marker protein CD9 
(mouse anti-human CD9; 1:1000; Chemicon Temecula, CA). 
 
Flow cytometry 
For flow cytometry, cells were dissociated with accutase, washed and stained with goat 
polyclonal anti-human B7H3 1:100 (R&D) or respective isotype control. As secondary 
antibody donkey Alexa 488 anti-goat antibody was used (Invitrogen, Karlsruhe, Germany) 
and fluorescence in a total of 10,000 events per condition was detected. Cells were analyzed 
with a BD-FACS Canto II flow cytometer (BD Biosciences, Heidelberg, Germany), final data 
were processed with the help of FlowJo flow cytometry analysis software (Tree Star, 
Ashland, OR, USA). Specific fluorescence intensity (SFI) was calculated by using the mean 
fluorescence signal of B7H3 divided by the mean fluorescence isotype signal.  
 
Quantitative Real-Time PCR (qRT-PCR) 
Total RNA was extracted using a RNA purification system (Qiagen, Hilden, Germany) and 
treated with RNase-free DNase I to remove genomic DNA (Roche, Mannheim, Germany). 
cDNA was prepared from 5 lg of total RNA using Superscript RNase H–Reverse 
Transcriptase (Invitrogen, Karlsruhe, Germany) and random hexamers (Sigma-Aldrich, 
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Taufkirchen, Germany). For qRT-PCR, gene expression was measured in an ABI Prism 
7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) with SYBR 
Green Master Mix (Eurogentec, Cologne, Germany) and primers at optimized concentrations 
[32]. Primers (Sigma-Aldrich) were selected to span exon–exon junctions. The sequence for 
human 4IgB7H3 and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were as follows: 4IgB7H3 forward primer 5’- CATCACACCCCAGAGAAGCC -3’, 
reverse primer 5’- AGAGGGCCGTG CGGTTGGCA -3’, GAPDH primers have been 
described [33]. Standard curves were generated for each gene and the amplification was 90–
100% efficient. Relative quantification of gene expression was determined by comparison of 
threshold values. All results were normalized to GAPDH. 
 
Mass spectrometry analysis 
Probe preparation: The band corresponding to 4IgB7H3-immunostained areas on the 
immunoblot were excised from SDS-PAGE. Gel pieces were consecutively washed with 
water and 50% acetonitrile, reduced with 10 mM DTT at 56°C for 1 h and alkylated with 
55 mM iodoacetamide (Sigma Aldrich) at 25°C for 30 min in the dark. After alkylation, gel 
plugs were repeatedly washed with water and 50% acetonitrile, dehydrated with 100% 
acetonitrile and air-dried. The dried gel plugs were reswollen in 40 mM ammonium 
bicarbonate containing 17 ng/µl sequencing grade modified trypsin (Promega, Mannheim, 
Germany). Following enzymatic digestion overnight at 37°C, peptides were repeatedly 
extracted with 0.1% TFA and acetonitrile/0.1% TFA 50:50 (v/v). The combined solutions 
were dried in a speed-vac for 2 h at 37°C. Peptides were redissolved in 5 µl 0.1% TFA by 
sonication for 10 min and applied for ESI-MS/MS analysis. 
Orbitrap Mass spectrometry analysis: NanoLC-MS/MS analysis was performed using the 
nanoACQUITY (Waters, Eschborn, Germany) coupled to a nanoESI- LTQ-Orbitrap mass 
spectrometer (Thermo Scientific, Bremen, Germany) using a stepped linear acetonitrile/water 
gradient ranging from 5% to 90% within 45 min. For enhancing the number of detected 
peptides, a targeted proteomics approach was performed for the identification of 4IgB7H3 
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(gi67188443, CD276 antigen isoform a, Homo sapiens). Only peptide masses obtained from 
an in silico trypsin digestion of 4IgB7H3 using a MS-Digest tool from the online 
ProteinProspector v5.7.2 software (UCSF, San Francisco, USA) were isolated and 
fragmented by the Orbitrap. Processed data were searched against the NCBInr database 
using the Mascot algorithm version v2.2.0 (Matrix Science Ltd., London, UK). The taxonomy 
homo sapiens was selected for Mascot searches. 
 
NK lysis assay 
Peripheral blood lymphocytes (PBL) were isolated from whole blood samples of healthy 
donors by Ficoll-Hypaque density gradient centrifugation. NK cells were then isolated from 
PBL by depletion of non-NK cells using a NK cell isolation kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Isolated CD56+/CD3- NK cells were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 medium  (PAA Laboratories, Pasching, Austria) containing 
10% fetal bovine serum (FBS; Perbio, Bonn, Germany) and 1000 U/ml interleukin-2 
(Immunotools, Friesoythe, Germany) for 5 days at 37°C / 5%CO2.  
NK cell cytotoxicity was assessed using 51chromium (51Cr)-release assay [34]. Briefly, 
labelled glioma cells (5x103/well) were seeded in triplicates into a U-shaped 96-well microtiter 
plate and incubated in triplicates with NK effector cells with effective target-to-effector ratios 
of 1:30, 1:10 and 1:3.  Minimum and maximum 51Cr release was determined by using target 
cells incubated in medium alone or 10% Triton-X-100 (Applichem, Darmstadt, Germany). 
After incubation at 37°C/5% CO2 for 4 h, supernatants were collected from each well and 
counted in a gamma counter (Packard, Meriden, CT, USA). Specific NK lysis in percent was 
calculated as follows: [Experimental 51Cr Release - Minimum Release] / [Maximum Release- 
Minimum Release] x100.  
 
Matrigel invasion assay  
The invasive properties of glioma cells were assessed in Boyden chamber assays (BD 
Biosciences), where a porous membrane (8 µm pore size) coated with matrigel matrix 
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separates upper and lower wells. Glioma cells were harvested in enzyme-free cell 
dissociation buffer (Gibco Life Technologies, Karlsruhe, Germany) and a total of 4x104 cells 
in culture medium were added in triplicates to the upper chamber [35]. NIH 3T3-conditioned 
medium (0.5 ml) was used as a chemoattractant in the bottom well. Cell invasion was 
evaluated by counting the number of cells that had migrated across the membrane in five 
independent fields and expressed as percentage of invasiveness relative to control. 
 
Spheroid invasion assay 
One x 106 GIC were seeded in neural sphere cell medium (NSCM; Invitrogen, Karlsruhe, 
Germany) and kept in culture until spheroids had formed. Extracellular matrix gel was 
prepared as described previously [29]. Glioma cell spheroids were seeded into the collagen 
gel solution in a 24-well plate in triplicates. After gelation, the gel was covered with medium 
and cultured at 37°C/5% CO2. Microscopic photographs of the area covered by each 
spheroid were taken at 0, 24, 48 and 72 h after implantation. For quantification, the mean 
area which was covered by invaded glioma cells at an indicated time point was measured in 
intervals of 24 h and compared with the area at 0 h. 
 
Animal experiments  
Animal work was approved by the governmental authorities (Regierungspräsidium Karlsruhe, 
Germany) and supervised by institutional animal protection officials in accordance with the 
National Institutes of Health guidelines Guide for the Care and Use of Laboratory Animals. 
 
Orthotopic brain tumor model 
A total of 1x105 human T269 4IgB7H3 knockdown or T269 control cells were stereotactically 
implanted into the right striatum of five 6-12-week-old athymic mice (CD1 nu/nu; Charles 
River Laboratories, Wilmington, MA, USA), respectively. Ten weeks after implantation, 
animals were sacrificed, brains removed and cryosectioned. To access infiltration 
immunostainings were conducted with rabbit anti-human nestin antibody (Millipore) after 
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fixation of cryosections with acetone. As secondary antibody, Alexa 488 anti-rabbit antibody 
(Invitrogen) was used.  
 
Subcutaneous tumor model: 
Flank injection of human glioma cells and systemic depletion of NK cells were performed as 
described previously [36]. Briefly, 1 x 107 human LN-229 B7H3 knockdown cells or LN-229 
sh-Ctrl. cells were injected s.c. into the right flank of CD1 nu/nu mice after mixing with an 
equal volume of liquid matrigel (BD Matrigel TM Basement Membrane Mix, BD Biosciences). 
NK-cell depletion was performed by biweekly i.p. injection of 1,5 µg/ml of rabbit anti-asialo 
GM1 antibody (Wako Chemicals, Duesseldorf, Germany) starting 2 days before tumor cell 
injection. Controls were injected with rabbit IgG (Calbiochem, Darmstadt, Germany). Tumor 
growth was regularly monitored using metric callipers. accordingly. Flow cytometric analysis 
of spleen cells with rat anti-mouse Dx5 (Ly49B) antibody from Caltag (Burlingame, CA) 
confirmed NK-cell depletion. After 20 days the mice were sacrificed, tumors were excised, 
and weighed.  
 
Immunohistochemistry 
Formalin-fixed paraffin-embedded tissue of human diffuse astrocytomas (WHO grade II, n = 
3), anaplastic astrocytomas (WHO grade III, = 7) and glioblastoma (WHO grade IV, n =13) 
were provided by the Department of Neuropathology, Institute of Pathology, University 
Hospital Heidelberg, Germany. Sections cut to 3 µm were processed using a Ventana 
BenchMark XT® immunostainer (Ventana Medical Systems, Tucson, AZ, USA). Staining 
procedure included a pretreatment with cell conditioner 1 (pH 8) for 60min, followed by 
incubation with either goat anti-human B7H3 antibody (1:200; R&D, Minneapolis, MN, USA) 
or mouse anti-human CD8 (1:50; Dako, Glostrup, Denmark) at 37°C for 32 min and, for 
detection of B7H3, application of rabbit anti-goat immunoglobulins (P0446, DAKO, Glostrup, 
Denmark) for 32 min at room temperature. Incubation was followed by Ventana standard 
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signal amplification, UltraWash, counterstaining with one drop of hematoxylin for 4min and 
one drop of bluing reagent for 4 min. For visualization, ultraView™Universal DAB Detection 
Kit (Ventana Medical Systems) was used. For quantitative analysis of the B7H3 staining 
pattern, the immunoreactive score (IRS) was applied. IRS was calculated as product of 
staining intensity and percentage of positive cells, determined as follows: staining intensity 
was subdivided into four groups, 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). 
Percentage of positive cells was regarded as 0 (none), 1 (<10%), 2 (10-50%), 3 (51-80%) 
and 4 (>80% positive tumor cells). Infiltration of CD8 positive cells was assessed in 4 GBM 
with high (IRS >8) and 4 GBM with low (IRS <8) B7H3 immunoreactivity. Of each case, four 
200x magnification fields were analyzed. Presence of respective cells was scored as either 0 
(no positive cells), 1 (single positive cells), 2 (single groups of positive cells), or 3 (several 
groups of >3 positive cells). 
 
Fluorescent immunohistochemistry 
The B7H3 colocalization studies on cryosections of human glioblastoma tissue samples were 
performed after acetone fixation and staining with a goat polyclonal anti-human B7H3 
antibody (R&D, Minneapolis, MN, USA), a mouse anti-human CD31 antibody (Dako), a 
mouse anti-human alpha-smooth muscle actin (SMA) antibody (Sigma Aldrich) and a rabbit 
anti-human nestin (Millipore). As secondary antibodies, a donkey anti-mouse Cy3 antibody 
(Dianova, Hamburg, Germany) and an Alexa 750 goat anti-rabbit antibody (Invitrogen) were 
used. Finally, sections were counterstained with 4,6-diamidino-2-phenylindol (DAPI) and 
analyzed with a Zeiss Axio Observer Z1 immunofluorescence microscope (Zeiss, 
Oberkochen, Germany). 
 
Clinical survival data 
Queries of the Repository of Molecular Brain Neoplasia Data (REMBRANDT, National 
Cancer Institute, Bethesda, MD) for (CD276) were conducted online in 2011 following the 
webpage’s instructions.  
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Statistical analysis  
Statistical significance was assessed by Student’s t-Test (Excel, Microsoft, Seattle, WA, 
USA). All in vitro experiments, reported here were performed at least three times in triplicate 
or more. For in vivo experiments five animals per group were operated. Survival data were 
plotted by the Kaplan-Meier method and analyzed by the log-rank test.  
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Results 
B7H3 is expressed in human glioma tissue specimens and cultured glioma cells  
B7H3 is detected in specimens of freshly dissected human glioma tissue by 
immunohistochemistry and is markedly upregulated in glioma tissue compared with the 
surrounding brain tissue at the infiltration zone (Fig. 1A). Here, strong B7H3 expression is 
found in close proximity to blood vessels. The degree of B7H3 expression correlated with the 
grade of malignancy of different gliomas (Fig. 1A). All of 18 glioblastoma samples tested by 
immunohistochemistry,(13 samples), and immunofluorescence analysis, (five samples), were 
positive for B7H3 (Fig. 1A,C and 4D). Queries of the NIH’s REMBRANDT brain tumor 
database, based on Affymetrix gene expression data and survival data, indicated in addition 
a correlation between decreased survival and increased gene expression of B7H3 in 
anaplastic astrocytomas (WHO grade III). In Glioblastoma this correlation is just under the 
level of significance (Fig.1B). 
To further characterize the localization of the focally enhanced B7H3-expression, co-
stainings with CD31 for endothelial cells, smooth muscle cell actin (SMA) for pericytes or 
nestin for glioma cells were done (Fig. 1C). These co-localization studies revealed that B7H3 
is expressed by endothelial cells and also weakly by SMA-positive cells but in particular by 
the primary glioma cells surrounding the vessels (Fig. 1CI). On the cellular level, B7H3 
protein was expressed in the cytoplasm and on cell membranes.  
Moreover, four glioma-initiating cell (GIC) cultures (Suppl. Fig. 1), which were established 
from human glioblastoma tissue and kept under stem cell conditions, expressed B7H3 
mRNA, as did five of five glioma cell lines. To rule out that expression of 4IgB7H3 in vessels 
of brain tumor tissue (Fig. 1) is due to soluble B7H3 from the glioma cells themselves we 
performed expression studies of B7H3 in cultivated human pericytes and human cerebral 
microvascular endothelial cells (hCMEC). The expression detected in hCMECs and pericytes 
was weaker compared with tumor cells (Fig. 2A). B7H3 protein of the predicted size of ~ 100 
kDa was detactable in all tested glioma cultures (Fig. 2A upper panel), but the 45 kDa 
2IgB7H3 could not be detected in the glioma samples. Finally, B7H3 was detected on the 
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surface of glioma cell lines and GIC cultures as assessed by flow cytometry (Fig. 2A). There 
was no significant difference in B7H3 expression between GIC cultures and cell lines (Fig. 
2A).  
In an attempt to detect the recently published [24] soluble 16.5 kDa fragment of B7H3 in cell 
culture supernatants, we used two different antibodies: one directed against a peptide 
sequence in the first N-terminal immunoglobulin-like extracellular domain, the other one 
detecting the entire extracellular protein moiety of 2IgB7H3 and in addition due to sequence 
homology also 4IgB7H3 (Suppl. Fig 3). The existence of a 16.5 kDa fragment could be 
substantiated neither in supernatant of glioma cell line cultures nor GIC cultures with these 
commercial antibodies (Fig. 2B).  
In order to further analyze the mechanism of soluble 4IgB7H3 secretion, we first examined 
whether 4IgB7H3 could be detected in the exosomal compartement of LN-229 cells. Indeed, 
4IgB7H3 co-localized with the exosomal marker CD9 [36] after exosome preparation but was 
not detected in the unconcentrated supernatant fraction (Fig. 2C). Comparing 4IgB7H3 
originating from cell lysates directly with its secreted form obtained from cell culture 
supernatants a size difference of about 5-7 kDa was detected in immunoblot analyses (Fig. 
2D). In nanoLC electrospray-tandem-massspectrometry analyses this size difference was 
confirmed, due to a missing peptide sequence of about 7 kDa in the supernatant probe. This 
part represents the intracellular and transmembrane fragment of 4IgB7H3 (Fig. 2D), which is 
not present in the concentrated supernatant fraction analysed by two different antibodies. 
From this we assume that after exosomal release of 4IgB7H3 by glioma cells a 93 kDa 
fragment is processed and can be detected in concentrated supernatant. 4IgB7H3 appears 
to be the major isoform of B7H3 expressed in glioblastoma. 
 
4IgB7H3 is released into the supernatant and inhibits NK-mediated lysis of glioma 
cells in vitro and in vivo. 
We next evaluated the functional activity of 4IgB7H3 expressed by glioma cells. 4IgB7H3 
was silenced in the glioma cell line LN-229 with a lentiviral system. The initial knockdown has 
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been about 80% effective, after clonal selection the knock-down reached 93% in clone 19 on 
the mRNA level. Immunoblot and flow cytometry reveal a clear reduction of 4IgB7H3 protein 
levels in lysates, supernatant and on the surface of the knockdown cells (Fig. 3A). Of note, 
the transfectants and control cells do not differ in morphology, generation time or 
clonogenicity (data not shown). LN-229 sh-4IgB7H3 cells were more susceptible to NK cell-
mediated lysis. The clonal knockdown was lysed best with around 60% specific lysis at a 
target to effector cell ratio of 1 to 30, the less-efficient B7H3-silenced pool transfectants 
showed an intermediate lysis at 40% while the controls were at 25% (Fig. 3B, left panel). 
Given that 4IgB7H3 is released into the supernatant, we also analyzed whether soluble 
glioma cell-derived 4IgB7H3 suppresses NK cell-mediated lysis. Hence, we performed NK 
lysis assays with LN-229 sh-4IgB7H3 clone 19 cells, which were susceptible to lysis, and 
supplemented supernatant of LN-229 sh-4IgB7H3 clone 19 or control cells. Compared with 
the specific NK-mediated lysis of LN-229 sh-4IgB7H3 clone 19 cells of around 60%, the 
specific lysis of these cells was reduced to 20% by coincubation with concentrated 
supernatant of control cells. This reduction of specific lysis was weaker after diluting the 
control supernatant 1:100. The supernatant of LN-229 sh-4IgB7H3 clone 19 cells does not 
reduce the lysis of LN-229 sh-4IgB7H3 clone 19 cells (Fig. 3B, right panel). We also 
generated 4IgB7H3 knockdown cells of the GIC culture T269, with a knockdown of 80% on 
mRNA level and a significant reduction on protein level measured by immunoblot and flow 
cytometry (Fig. 3C). T269 sh-4IgB7H3 cells, too, have been significantly more susceptible to 
NK cell-mediated lysis (Fig. 3D). Taken together, these data indicate that 4IgB7H3 and its 
secreted form suppress NK-cell mediated lysis of glioma cells and GICs in vitro.  
To further characterize the impact of 4IgB7H3 expression in vivo, subcutaneous tumors were 
generated with LN-229 sh-4IgB7H3 and control cells. Tumor growth was monitored in LN-
229 sh-4IgB7H3 and control cells in NK cell-depleted compared with control-IgG-antibody 
treated mice [37]. Here, a significant difference in tumor growth and tumor weight at the end 
of the experiment was only detected between LN-229 sh-4IgB7H3 derived tumors in NK cell-
depleted versus non-depleted animals. In NK cell-retaining animals LN-229 sh-4IgB7H3 
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derived tumors grew significantly smaller and were lighter at the end of the experiment. In 
LN-229 sh-control derived tumors NK cell depletion had no significant impact on tumor 
growth and weight (Fig. 4A-B) demonstrating that silencing of 4IgB7H3 made glioma cells 
susceptible to NK cell dependant cytotoxicity. Moreover, human glioblastoma samples 
showed a highly significant inverse correlation between B7H3 expression and invasion of 
CD8 positive immune cells. Co-staining of B7H3 and CD8 revealed that the influx of CD8 
positive cells is significantly higher in B7H3-low expressing tumors compared with B7H3-high 
expressing tumors (Fig. 4C-D) 
 
Regulation and cleavage of 4IgB7H3 in glioma cells differ from other tumor entities 
and immune cells 
To evaluate how 4IgB7H3 expression is regulated and how soluble 4IgB7H3 is cleaved from 
the cell surface, we assessed the influence of proteinkinase C activation by phorbol 12-
myristate 13-acetate (PMA), inhibition of MMP by ilomastat [22], inhibition of TGF- with 
LY2157299 or a furin inhibitor and hypoxia on 4IgB7H3 levels. All compounds are sufficiently 
active in control assays (data not shown). 4IgB7H3 was neither induced by PMA on mRNA 
level nor on the protein level in cell lysates or with regard to the 93 kDa soluble form in the 
supernatant of glioma cells (Suppl. Fig.2A). Moreover, cleavage of 4IgB7H3 from the surface 
of the glioma cell line LN-229 (Suppl. Fig.2B) and GIC cultures T325 (Suppl. Fig.2A,B) was 
not influenced by inhibition of MMP with ilomastat as shown before for monocytes, DC, 
activated T-cells and various carcinoma cells. Inhibition of TGF-, which is known to 
suppress NK cells and to convey immune escape of gliomas in various manners [38], did not 
result in down-regulation of 4IgB7H3 nor did hypoxia influence its expression (Suppl. Fig.2A). 
Further experiments evaluating the regulation of 4IgB7H3 in glioma cells did not show a 
significant upregulation of 4IgB7H3 on the mRNA level nor in the supernatant of LN-229 cells 
following irradiation, interferon--, dexamethasone- or H2O2-treatment (Suppl. Fig 2C).  
 
 
Lemke and Pfenning et al. 
 
  18
 
4IgB7H3 modulates the invasive phenotype in glioma cells in vitro and in vivo  
Mounting evidence suggests that 4IgB7H3 is involved in tumor cell migration and 
invasiveness. Therefore, Boyden chamber matrigel and spheroid invasion assays were 
performed with LN-229 cells as well as with the GIC culture T269. LN-229 sh-4IgB7H3 cells 
displayed reduced transmigration compared with control cells in these assays (Fig. 5A). 
Interestingly, the invasive phenotype was partly restored in LN-229 sh-4IgB7H3 cells when 
invasion assays were conducted with supplementation of concentrated supernatant of LN-
229 control cells (Fig. 5B). There was also a reduction in the invasiveness of LN-229 control 
cells when the cells were incubated with supernatant from LN-229 sh-4IgB7H3 cells instead 
of supernatant from control cells during the invasion experiments (Fig. 5B), indicating that 
glioma supernatant may have an anti-invasive property, which can be partly overcome by the 
pro-invasive effect of soluble 4IgB7H3. To verify this proinvasive effect of 4IgB7H3 in primary 
glioma cells, primary 4IgB7H3-silenced T269 GICs were further used in a functional invasion 
assay. This spheroid invasion assay demonstrated a significant reduction of the invasive 
phenotype in T269 cells after 4IgB7H3 gene silencing (Fig. 5C).  
Aiming at confirming the in vitro data in an in vivo model, T269 sh-4IgB7H3 knock-down or 
control cells were orthotopically implanted into the brains of CD1 nu/nu mice. Ten weeks 
later, animals were sacrificed and tumor invasion was assessed by staining of the tumor cells 
with anti-human nestin antibody. Brain sections displayed a highly infiltrative tumor growth 
pattern with tumor cells reaching brain regions in the ipsi- and contralateral hemisphere far 
off the implantation site in T269 control xenograft animals (Fig. 6, upper panel). In contrast, 
clearly defined bulky tumors were found in T269 sh-4IgB7H3 xenografted brains without 
detectable tumor cells in ipsi- or contralateral brain regions distant from the implantation site 
(Fig. 6, lower panel).  
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Discussion 
Glioblastoma is a paradigmatic tumor for tumor-associated immunosuppression. B7H3 is a 
novel member of the B7-family of costimulatory proteins. As parts of our efforts to 
characterize and understand the immune phenotype of glioblastoma we here report that 
B7H3 is expressed in human glioblastoma tissue by both glioblastoma and endothelial cells 
(Fig. 1 and 2A). Glioma cells, which surround the blood vessels preferentially express B7H3. 
In addition to that, expression correlates significantly with increasing tumor grade and is 
associated with poor survival within WHO grade III gliomas. 
By mass spectrometry and immunoblot analysis, we identified that 4IgB7H3 but not the 
smaller isoform 2IgB7H3 was preferentially expressed by different GIC cultures and glioma 
cell lines what was not determined in immune histochemistry analysis due to the lack of 
isoform specific antibodies (Suppl. Fig.3). Furthermore, it was demonstrated that 4lgB7H3 is 
secreted in exosomes into the supernatant of glioma cells and finally processed to a soluble 
form of about 93 kDa. Interestingly, this soluble 4IgB7H3 is not the 16.5 kDa soluble form of 
B7H3 postulated in non-malignant and malignant cells before [22]. Although two different 
antibodies were used, the one detecting whole extracellular protein, the other one the first 
immunoglobulin-like domain of the extracellular N-Terminus, we could not detect the 
published fragment of about 16.5 kDa in the supernatant of glioma cells. Here, the soluble 
fragment was about 7 kDa smaller than 4IgB7H3 originating from cell lysates (Fig. 2). In an 
attempt to further characterize the regulation and cleavage mechanism of B7H3 in 
glioblastoma, the cells were incubated with phorbol myristate acetate (PMA), which was 
published to induce B7H3 on immune and tumor cells [9, 39]. This regimen had no effect on 
B7H3 expression in glioblastoma cells on mRNA or protein level, neither did the inhibition of 
MMP, which have been suggested to cleave soluble B7H3 from the surface of tumor cells 
[22]. We finally evaluated whether blockage of TGF- activation with a furin inhibitor in the 
glioblastoma cell line LN-229 influenced 4IgB7H3 expression since TGF- is known to be 
responsible for a variety of immunosuppressive and proinvasive effects [5, 6, 8, 20]. 
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However, TGF- inhibition did neither result in the down-regulation of 4IgB7H3 nor its soluble 
form (Suppl. Fig.2).  
Importantly, 4IgB7H3 was functional in the glioblastoma cell line LN-229 and the GIC culture 
T269 and suppressed NK cell-mediated tumor lysis in vitro (Fig. 2) as well as in vivo (Fig. 3). 
In attempt to illucidate the immunosuppressive function of B7H3 in human glioblastoma we 
performed co-localization studies of B7H3 expression and CD8 positive cells. Here, a 
significant higher influx of CD8 positive cells in B7H3 low expressing tumors was detected 
compared with B7H3 high expressing tumors. As CD8 is a marker for cytotoxic T-cells which 
were also published to be suppressed by B7H3 [20] and NK-cells this data provide further 
evidence for an immunosuppressive function of B7H3. Furthermore, 4IgB7H3 exerted a 
proinvasive effect in glioblastoma cells in vitro (Fig. 5). We could additionally demonstrate the 
proinvasive effect of 4IgB7H3 in the GIC compartment in vivo: the highly invasive phenotype 
of the GIC culture T269 was significantly reduced by 4IgB7H3 gene silencing (Fig. 6). 
Interestingly, native glioblastoma-derived soluble 4IgB7H3 suppresses NK lysis and 
enhances glioblastoma cell invasiveness in vitro. Insofar, our data let us to postulate that NK 
cell suppression and the pro-invasive effect attributed to 4IgB7H3 expression in different 
tumor entities [39] are in fact exerted by membrane-bound and soluble B7H3, which was until 
now only evaluated for its diagnostic and prognostic capacity [22, 23, 40]. Finally, as soluble 
4IgB7H3 was sufficient to restore the invasiveness of 4IgB7H3-silenced LN-229 cells, the 
presence of a yet unknown counter-receptor must be postulated on glioblastoma cells, too.  
To summarize, our data provide new insights on the role of B7H3 expression in glioblastoma. 
There is an immunosuppressive function of 4IgB7H3 in glioblastoma similar to other tumor 
entities. This is also true for a pro-invasive phenotype. These effects can be exerted by 
secreted soluble 4IgB7H3 on its own leading to the assumption that the yet unidentified 
counter-receptor is expressed on immune and glioblastoma cells. Glioblastoma unlike non-
malignant cells do not generate and release the 16.5 kDa B7H3 fragment into the 
supernatant analyzed by commercially available antibodies. Our data support a fragment of 
about 93 kDa to exert that effect rather than a small 16.5 kDa fragment.  
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These data provide a therapeutic rationale to ameliorate treatment of glioblastoma by 
blockage of 4IgB7H3. First attempts to use 4IgB7H3 as a therapeutic target have been made 
recently with an antibody against 4IgB7H3 used to track neuroblastoma cells without 
intending to block 4IgB7H3 function itself [41], and a pseudomonas immunotoxin-coupled 
anti-B7H3 antibody to track glioblastoma xenograft tumors [42]. Further experiments are 
needed to evaluate 4IgB7H3 as a target in the treatment of 4IgB7H3-expressing tumors.  
 
 
Figure Legends 
Figure 1. Expression of B7H3 in human glioma tissue and correlation with the grade of 
malignancy 
(A) Gliomas of different WHO grade were analyzed for B7H3 expression by 
immunohistochemistry. Representative figures and statistical analysis are presented. B7H3 
expression is enhanced in proximity to the blood vessels (specimen 1, arrows). Specimen 2 
demonstrates upregulated B7H3 in the tumor compared with the surrounding brain tissue 
(arrow heads). (B) Kaplan-Meier survival plot according to Rembrandt queries shows survival 
of glioma patients with intermediate and high B7H3 expression levels. (C) 
Immunofluorescence microscopy (I-IV) was applied to detect B7H3 in three different 
glioblastoma specimens (T1462, T1297, T1563). Vessels are visualized by CD31 staining, 
pericytes are stained with -smooth muscle cell actin (-SMA), glioma cells are marked by 
nestin staining, nuclei are counterstained with DAPI. (I1-2) Glioblastoma cells (white 
arrowheads) surrounding blood (grey arrowheads) vessels exhibit a higher expression of 
B7H3. 
 
Figure 2. Expression and secretion of 4IgB7H3 by glioma cells, pericytes and endothelial 
cells.  
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(A) Expression of 4IgB7H3 in pericytes and endothelial cells as well as GIC (black bars) and 
glioma cell lines (white bars) on mRNA or protein levels (right, upper panel) and on the cell 
surface of GIC cultures (right, lower panel) is presented.  
(B) 4IgB7H3 in LN-229 glioma cells and GIC culture S24 was detected in lysates and in 
concentrated supernatant. A ~93 kDa fragment was substantiated in the supernatant but no 
16.5 kDa fragment. -tubulin was chosen as loading control for cell lysates and Ponceau 
staining for supernatant. (C) Exo preparation demonstrates that 4IgB7H3 is released within 
the exosomal compartment from the glioma cell line LN-229. CD9 staining was used as a 
exosomal marker. Unconcentrated supernatants (SN) are negative while lysates (Lys) are 
positive for for 4IgB7H3 and CD9.  
(D) Protein size analyzes of 4IgB7H3 in LN-229 whole cell lysates (Lys) and concentrated 
supernatant (SN) by immunoblot show size differences of whole and soluble 4IgB7H3. 
Positions of identified peptides (bold letters) in human 4IgB7H3 amino acid sequence 
deriving from lysates and supernatant analyzed by nanoLC-ESI-MSMS (right panel) as well 
as illustrative sketch visualizing hypothetical position of soluble 4IgB7H3 processing 
(interrupted line). 
 
Figure 3. Increased susceptibility of LN-229 4IgB7H3 sh-cells to NK cell-mediated lysis. 
(A) Polyclonal knock-down and clonal selection (clone 19) of 4IgB7H3 in LN-229 cells were 
performed. Knock-down efficiency on mRNA level (left panel), protein level (middle panel) 
and on the cell surface evaluated by flow cytometry are illustrated (right panel).  
(B) LN-229 sh-4IgB7H3 (polyclonal or clone 19), sh-control cells, or LN-229 sh-4IgB7H3 (left 
panel) as well as clone 19 cells supplemented with supernatant (SN) derived from clone 19 
or control cells (right panel) were incubated with activated NK cells for 4 h at the indicated 
effector to target cell ratios.  
(C) Knock-down of 4IgB7H3 in GIC culture T269 was performed and efficiency evaluated on 
mRNA level by qPCR (left panel), on protein level by immunoblot analysis and by flow 
cytomety (right panel).  
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(D) Activated NK cells were incubated with T269 sh-4IgB7H3 or sh-control cells and NK cell-
mediated lysis [%] has been evaluated. Representative results from three independent NK 
lysis experiments are depicted.  
Data represent mean and standard error of the mean (SEM); n=5; *p<0.05 relative to 
controls. 
 
Figure 4. B7H3 exerts an immunosuppressive function in vivo 
(A) Tumor size of subcutaneously injected LN-229 shB7H3 and control cells were monitored 
in NK-cell depleted (+Asialo) and control treated (+ Isotype) animals. Only the tumors which 
developed from LN-229 shB7H3 cells growing in mice with NK cells (dotted line) are 
significantly smaller. 
(B) Representative images of explanted tumors and statistical analysis of tumor weight at the 
end of the experiment. 
(C) B7H3 high-expressing human glioblastoma tissue (specimen 1) shows a reduced 
infiltration of CD8 positive immune cells compared with B7H3 low-expressing human 
glioblastoma tissue (specimen 2). 
(D) Statistical analysis of B7H3 high- and low-expressing human glioblastoma tissues 
demonstrates a stronger invasion of CD8 positive cells in B7H3 low-expressing tumors. 
 
Figure 5. 4IgB7H3 mediates a proinvasive phenotype in glioma cells in vitro. 
(A) LN-229 sh-4IgB7H3 (polyclonal knockdown and clone 19) and sh-control glioma cells or 
(B) clone 19 and sh-control cells incubated each with concentrated supernatant (SN) of 
control or clone 19 cells were analyzed for invasiveness in a matrigel invasion chamber 
assay. Invaded cells were counted in five independent fields. Invasion is expressed as 
percentage in relation to sh-control cells without supernatant (scale bars: 100 µm; data 
represent mean and standard error of mean (SEM); n=3, p<0.05). Representative 
photographs of the Boyden chambers are depicted. (C) T269 control or sh-4IgB7H3 cells 
were analyzed for their invasive properties in a spheroid invasion assay. The area covered 
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by invaded cells from each spheroid was measured in intervals of 24 h. Data represent mean 
and SEM (n=3). Representative glioma spheroids are shown (scale bars 100 µM). 
 
Figure 6. 4IgB7H3 drives the proinvasive phenotype of glioblastoma in vivo. 
Immunohistological analysis of (A) T269 control and (B) T269 sh-4IgB7H3 tumor bearing 
CD1 nu/nu mice. T269 tumor cells were detected by immunoflurescent anti-human nestin 
staining. Asterisks show areas with a higher magnification.  
 
Suppl. Figure 1. GIC cultures used for this work fulfill the criteria of tumor-initiating cells. 
 Stem cell characteristics of the used GIC cultures are shown exemplary for T269. (A) T269 
forms spheres when cultured in serum free medium supplemented with the growth factors 
EGF and bFGF. (B and C) T269 is positive for the progenitor marker nestin and can be 
differentiated by growth factor removal and serum supplementation. In response to 
differentiation, Tuj1 and GFAP are upregulated as demonstrated with immune fluorescence 
microscopy and flow cytometry. (D) T269 is highly tumorigenic after orthotopic implantation 
of as few as 50 cells into CD1 nu/nu mouse brains and forms a highly invasive tumor as 
demonstrated by HE staining. (E) Shows tumor initiation capacity of GIC cultures T269, 
T325, T323 and T1 after orthotopic implantation of 103 and 5 x 104 cells in CD1 nu/nu mice. 
 
Suppl. Figure 2. Regulation of 4IgB7H3-expression and cleavage of soluble 4IgB7H3. 
(A) Relative 4IgB7H3 mRNA or protein levels in lysates and supernatant as well as protein 
surface levels were evaluated in LN-229 after treating the cells with hypoxia, ilomastat, a 
furin-inhibitor and PMA (grey bars). Control treatments (white bars) show no significant 
differences. 
(B) Ilomastat does not alter the content of B7H3 on the surface of GIC culture T325 in flow 
cytometry. 
(C) Irradiation with 8 Gy, treatment with H2O2, dexamethasone and IFN- do neither increase 
4IgB7H3 expression on mRNA level nor in the supernatant. 
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Suppl. Figure 3. 
Anti-human B7-Homolog3 antibody from R&D is directed against Leu29-Pro245 (red color) of 
2IgB7H3. The illustration demonstrates sequence homology (red) of this section in 2Ig and 
4IgB7H3 explaining detection of  both isoforms by the polyclonal antibody ... 
 
Suppl. Figure 4. 
In order to prove the specificity of the 4IgB7H3 stains for flow cytometry, 4IgB7H3-containing 
supernatant of LN-229 wild type cells was added to the cells during the staining procedure. 
This measurement led to a reduction of the fluorescence intensity (grey curve) compared 
with the untreated probes (black curve) while the isotype control remained unchanged. 
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